Author: Customer Service
DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTE AU 28 FEVRIER 2026
Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMFNombre d’actions composant le capital social
232 848 588Nombre de droits de vote théoriques
254 398 618Nombre de droits de vote exerçables
250 466 446Cette déclaration est en ligne sur le site internet d’Elis www.elis.com
DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 28 FEBRUARY 2026Total number of shares
232,848,588Theoretical number of voting rights
254,398,618Number of exercisable voting rights
250,466,446This disclosure is on Elis web site www.elis.com
Contacts
Nicolas Buron, Director of Investor Relations, Financing & TreasuryPhone: +33 1 75 49 98 30 –...
Interim report Q1 2025/26
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Roblon’s revenue and earnings for the first quarter of 2025/26 fell short of Management’s guidance at the beginning of the financial year
The Board of Directors of Roblon A/S has today considered and approved the interim report for the first three months of 2025/26.
Highlights Q1 2025/26
Consolidated revenue amounted to DKKm 29.8, against DKKm 51.1 in the year-earlier period. Whereas the FOC product group improved, the revenue decline in the Composite area was more pronounced than expected.
EBITDA before special items was a loss of DKKm 6.3 (a profit of DKKm 6.7).
EBIT before special items was a loss of DKKm 9.2 (a profit of DKKm 3.0), and profit/loss from continuing operations before tax was a loss of DKKm 10.4 (a profit of DKKm 4.6).
While Management did expect a lower level of activity in the first quarter of 2025/26, both revenue...
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Written by Customer Service on . Posted in Public Companies.
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting.
This premier annual gathering of neuro‑ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders.As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential global scientific meeting in neuro‑ophthalmology, reinforcing its commitment to advancing scientific progress in...
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
Written by Customer Service on . Posted in Public Companies.
ZUG, Switzerland, 16 March, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced the presentation of the ACUITY Phase 2 data with Privosegtor at the North American Neuro-Ophthalmology Society (NANOS) 52nd Annual Meeting.
This premier annual gathering of neuro-ophthalmology experts worldwide provides a scientific forefront platform for presenting transformative clinical data amongst leading clinicians, researchers, and thought leaders.
As a Platinum Sponsor of the 2026 Congress, Oculis is proud to support the most influential global scientific meeting in neuro-ophthalmology, reinforcing its commitment to advancing scientific progress in this field.
NANOS...
Niu Technologies Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
— Fourth Quarter Revenues of RMB 676.2 million, down 17.4% year over year
— Fourth Quarter Net Loss of RMB 88.1 million, compared with RMB 72.5 million in the same period of 2024
— Full Year Revenues of RMB 4,307.9 million, up 31.0% year over year
— Full Year Net Loss of RMB 39.4 million, compared with RMB 193.2 million in 2024
BEIJING, March 16, 2026 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Fourth Quarter 2025 Financial HighlightsRevenues were RMB 676.2 million, a decrease of 17.4% year over year
Gross margin was 15.3%, compared with 12.4% in the fourth quarter of 2024
Net loss was RMB 88.1 million,...
Share buyback programme – week 11
Written by Customer Service on . Posted in Public Companies.
Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeDanish Financial Supervisory AuthorityOther stakeholders
Date 16 March 2026
Share buyback programme – week 11
The share buyback programme runs in the period 2 February 2026 up to and including 8 May 2026, see company announcement of 30 January 2026.
During the period the bank will thus buy back its own shares for a total of up to DKK 500 million under the programme, but to a maximum of 600,000 shares.
The programme is implemented in compliance with EU Commission Regulation No. 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No. 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation.
The following transactions have been made under the programme:Date
Number of shares
Average purchase price (DKK)
Total purchased under the programme...
GN Store Nord A/S enters into agreement to sell its Hearing business to Amplifon S.p.A. for DKK 17.0 billion
Written by Customer Service on . Posted in Public Companies.
Today, GN Store Nord A/S (“GN”) has entered into a definitive agreement for the sale of GN’s Hearing business to Amplifon S.p.A. (“Amplifon”), a leading global hearing care retailer. The transaction values the Hearing business at DKK 17.0 billion1 on a cash-free and debt-free basis and will be settled with DKK 12.6 billion2 in cash and 56 million shares in Amplifon. The transaction is subject to customary regulatory approvals and completion of the Hearing business separation from GN and is expected to complete by the end of 2026.
Amplifon and GN will together create a global integrated leader in audiology combining hearing technology leadership with high-quality, innovative hearing care to offer comprehensive solutions to both audiology professionals and patients. The combination will create the industry leader in hearing care solutions...
SHELL PLC FOURTH QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
Written by Customer Service on . Posted in Dividend Reports And Estimates.
SHELL PLC FOURTH QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
March 16, 2026
The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the fourth quarter 2025 interim dividend, which was announced on February 5, 2026 at US$0.372 per ordinary share.
Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by March 6, 2026 will be entitled to a dividend of US$0.372, €0.3227 or 27.87p per ordinary share, respectively.
Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros at the euro rate per ordinary share shown above. Absent any...
19/2026・Trifork Group: Weekly report on share buyback
Written by Customer Service on . Posted in Public Companies.
Schindellegi, Switzerland – 16 March 2026
Trifork Group AGCompany announcement no. 19/2026
Weekly report on share buyback
On 27 February 2026, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 March 2026 up to and including no later than 31 December 2026. For details, please see company announcement no. 15 of 27 February 2026.
Under the share buyback program, Trifork will purchase shares for up to a total of DKK 75 million (approximately EUR 10 million).
Under the program, the following transactions have been made:Date
Number of shares
Average purchase price (DKK)
Transaction value...
OSE Immunotherapeutics Announces its 2026 Financial Calendar
Written by Customer Service on . Posted in Public Companies.
Nantes, France, March 16, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. Information
Date* 2025 Full-Year Financial Update and Statements
April 29, 20262026 1Q Cash Position
April 30, 2026Annual General Meeting
June 24, 20262026 First-Half Financial Update and Statements
September 28, 20262026 3Q Cash Position
October 27, 20262026 4Q Cash Position
January 26, 2027* This financial calendar is provided for information only and may be subject to changes. The Company’s updated financial calendar is available on its corporate website.ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet...
